Thank you for visiting nature.com. You are using a browser version with limited support for CSS. To obtain
the best experience, we recommend you use a more up to date browser (or turn off compatibility mode in
Internet Explorer). In the meantime, to ensure continued support, we are displaying the site without styles
and JavaScript.
The results of a phase IIb study suggest that ianalumab, an anti-BAFF receptor antibody, could have disease-modifying effects in primary Sjögren syndrome.
A new study shows that resident memory T cells that accumulate in the synovium of arthritic joints contribute to site-specific disease flare, and could present a new therapeutic target.
Researchers have found that hypoxia in articular cartilage is associated with expression of DOT1L, which protects against cartilage damage in a mouse model of osteoarthritis.
New research suggests that macrophage migration inhibitory factor (MIF) might contribute to spondyloarthritis (SpA) by enhancing type 3 immunity, and could be a potential therapeutic target.
A new study suggests that DNMT3A mutations associated with clonal haematopoiesis of indeterminate potential are linked to osteoporosis through IL-20-mediated osteoclastogenesis.
Inhibition of the soluble epoxide hydrolase enzyme prevents metabolism of anti-inflammatory epoxyeicosatrienoic acids and reduces pain in a mouse model of osteoarthritis.
A study published in Nature Biomedical Engineering reports a new biomimetic lubricant that can help restore cartilage in rats with post-traumatic osteoarthritis.
Researchers have created therapeutic implants containing cells engineered to release anti-inflammatory biologic drugs in response to changing endogenous inflammatory signals.
New research shows that cartilage engineered from nasal chondrocytes can integrate with osteoarthritic joint tissues in animal models, and provides early evidence of clinical benefits in patients with knee osteoarthritis.
A new study finds that a small-molecule inhibitor of IRAK4 blocks inflammation and pathophysiological processes in rheumatoid arthritis and systemic lupus erythematosus.
A study in Genome Biology reports the fine-mapping of rheumatoid arthritis risk loci in synovial fibroblasts and provides evidence of a causal role for these cells in the heritability of this disease.
A study of human immune-cell populations has shown that IFNγ from synovial natural killer cells can activate a subset of pro-inflammatory HLA-DR+CD90+ synovial fibroblasts that is greatly expanded in rheumatoid arthritis.
Targeted nanoparticles that bind to exposed type II collagen in injured joints and promote localized downregulation of Mmp13 expression represent progress towards a disease-modifying osteoarthritis drug.
A population of FOXP3+ regulatory T cells that express RANKL are capable of promoting osteoclast formation and accelerate bone loss in a mouse model of arthritis.
New research shows that metabolic modulation can restore immune tolerance induction by anti-CD45RB antibodies in lupus-prone mice and reduce systemic lupus erythematosus-like pathology.
Chimeric antigen receptor (CAR) T cell therapy has been used to treat a patient with systemic lupus erythematosus, marking the first time this approach has been successfully used to treat an autoimmune disease.
A study published in Nature shows the effects of ageing on skeletal stem cells (SSCs) and how aged SSCs affect haematopoiesis, bone turnover and fracture repair.
New research demonstrates that antibodies from patients with fibromyalgia induce sensory hypersensitivities in recipient mice, suggesting an autoimmune basis for the disease as well as new therapeutic possibilities.
